Cena / účtovná hodnotae spoločnosti Ayala Pharmaceuticals
Aká je hodnota metriky Cena / účtovná hodnotae spoločnosti Ayala Pharmaceuticals?
Hodnota metriky Cena / účtovná hodnotae spoločnosti Ayala Pharmaceuticals Inc. je 0.00
Aká je definícia metriky Cena / účtovná hodnotae?
Cena / učtovná hodnota (Price to book ratio) ukazateľ vyjadruje pomer medzi hodnotou spoločnosti a book value spoločnosti, čo je hodnota čistých aktív.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Cena / účtovná hodnotae spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Ayala Pharmaceuticals
Čomu sa venuje spoločnosť Ayala Pharmaceuticals?
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Firmy s metrikou cena / účtovná hodnotae podobnou spoločnosti Ayala Pharmaceuticals
- Hodnota metriky Cena / účtovná hodnotae spoločnosti GBL Industries je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti GoPro je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti ams AG je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Taronis Fuels je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Bang & Olufsen a/s je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Noble plc je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Ayala Pharmaceuticals je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Montello Resources je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Unit je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Oasmia Pharmaceutical AB (publ) je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Chaparral je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Hi Crush Inc je 0.00
- Hodnota metriky Cena / účtovná hodnotae spoločnosti Savencia SA je 0.00